Loading
A phase 1/2 trial of CIS-DPI in non-small-cell lung cancer, run by Inhatarget Therapeutics, now recruiting.
Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06896890 by Inhatarget Therapeutics, with 32 participants planned, started 2023-06-23 and due to reach its primary completion in 2026-10-01. Interventions recorded: CIS-DPI.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Platinum agents, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/